Industry
Featured experience
Endo $6.7 billion merger with Mallinckrodt
We are advising Endo on the transaction
GSK up to $1.15 billion acquisition of IDRx
We are advising GSK on the transaction
Galderma Group CHF2.3 billion ($2.6 billion) IPO
We advised Galderma on its IPO
Galapagos NV €278.7 Million Global Offering Of Ordinary Shares
Davis Polk advised the several underwriters, in connection with Galapagos NV’s global offering of 7,532,499 of its ordinary…
Anthem $1.25 Billion Equity Units Offering
Davis Polk advised the joint book-running managers in connection with a registered public offering by Anthem, Inc. of $1.25…
Laboratory Corporation of America Holdings $2.9 Billion Senior Notes Offering
Davis Polk advised the joint book-running managers and representatives of the underwriters on a public offering by…
Warner Chilcott $8.5 billion acquisition by Actavis
Davis Polk is advising Warner Chilcott plc in connection with its approximately $8.5 billion acquisition by Actavis, Inc. in…
HHS-OIG Drops Potential Action Against Howard Solomon
On August 5, 2011, the Office of Inspector General for the Department of Health and Human Services dropped a potential…
Successful patent litigation jury verdict for VNUS Medical
Davis Polk represented VNUS Medical in patent infringement litigation since 2005 in the Northern District of California…
Shareholder Plaintiff's Fee Petition in Roche-Ventana Merger Denied
On January 20, 2009, the Delaware Court of Chancery heard oral argument and denied a Ventana Medical Systems, Inc…